No, this is not an injection of medication in to the eye. It is a light based therapy.

Each Valeda treatment takes less than 5 minutes per eye.

Usually yes.

Your doctor will determine eligibility.

Photobiomodulation is a light-based therapy that uses specific wavelengths of visible and near-infrared light to stimulate cellular energy production within the mitochondria. By increasing ATP production and reducing oxidative stress, PBM helps support healthier retinal cells and may improve visual function in appropriately selected patients with Dry Age-Related Macular Degeneration.

No. Valeda is completely non-invasive and painless. There are no injections, incisions, or medications involved. During treatment, patients simply look into the device while therapeutic light is delivered to the retina. Most patients find the treatment relaxing and comfortable.

No. Valeda uses low-level light therapy, not retinal laser treatment.

Coverage varies and may depend on your insurance plan and current reimbursement policies. Our team can help discuss financial considerations prior to treatment.

A typical treatment cycle consists of nine treatment sessions completed over approximately three to five weeks. Based on current clinical protocols, treatment is generally repeated every four months. Your doctor will recommend a schedule based on your retinal findings and visual goals.

Valeda has demonstrated an excellent safety profile in clinical studies. The most common effect is a temporary afterimage (called photostress) that usually resolves within 15–30 seconds after treatment. No treatment-related serious adverse events were reported in the major clinical trials. Your doctor will review your medical history to determine whether Valeda is appropriate for you.

Yes. Most patients are able to return to work, drive, read, and resume their normal daily activities immediately following treatment. No recovery period is required.

Valeda is contraindicated with individuals with epilepsy. It may not be appropriate for individuals with certain photosensitivity disorders. A comprehensive retinal examination and review of your medical history will help determine whether you are a good candidate for treatment.

No. There is currently no cure for Dry AMD. Valeda is designed to improve visual acuity and support healthier retinal function in appropriately selected patients. Early treatment may help preserve vision and slow functional decline, but individual results vary.

The best candidates are patients diagnosed with Dry Age-Related Macular Degeneration who meet the clinical criteria for treatment. During your consultation, your doctor will perform advanced retinal imaging and determine whether Valeda is the right option for your eyes.